Spinogenix Wins Grant to Advance Testing of Potential Oral Therapy

Spinogenix Wins Grant to Advance Testing of Potential Oral Therapy

282130

Spinogenix Wins Grant to Advance Testing of Potential Oral Therapy

Spinogenix has been awarded a research grant from the U.S. Department of Defense (DOD) to further test its lead compound as a potential treatment of amyotrophic lateral sclerosis (ALS), the company announced. “We are pleased that the DoD has recognized the potential of our novel drug candidate to change the course of disease progression in ALS,” Stella Sarraf, PhD, founding CEO at Spinogenix, said in a press release. The grant’s amount and its duration were…

You must be logged in to read/download the full post.